Commentary: A gastrin antagonist against carcinoids - Implications for PPI-induced hypergastrinaemia

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 2, 2013, Pages 276-277

  McCarthy, D M ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHROMOGRANIN A; GASTRIN; NETAZEPIDE; OCTREOTIDE; PROTON PUMP INHIBITOR; SOMATOSTATIN;

ATROPHIC GASTRITIS; CHRONIC ATROPHIC GASTRITIS; HUMAN; HYPERGASTRINEMIA; NOTE; PERNICIOUS ANEMIA; PRIORITY JOURNAL; STOMACH CARCINOID; TUMOR RECURRENCE; TUMOR REGRESSION;

BENZODIAZEPINONES; CARCINOID TUMOR; CHROMOGRANIN A; FEMALE; HUMANS; MALE; PHENYLUREA COMPOUNDS; RECEPTOR, CHOLECYSTOKININ B; STOMACH NEOPLASMS;

EID: 84872850992     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12135     Document Type: Note

References (6)

1. Fossmark R, Sørdal Ø, Jianu CS, et al,. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012; 36: 1067-75.
2. McCarthy DM,. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26: 624-31.
3. Kokkola A, Sjoblom SM, Haapiainen R, Sipponen P, et al,. The risk of gastric carcinoma and carcinoid tumors in patients with Pernicious Anemia. A prospective follow-up study. Scand J Gastroenterol 1998; 33: 88-92.
4. Borch K, Ahren B, Ahlman H, et al,. Gastric Carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 64-73.
5. Brenna E, Waldum HL,. Trophic effect of gastrin on the enterochromaffin-like cells of the rat stomach: establishment of a dose-response relationship. Gut 1992; 33: 1303-6.
6. Metz DC,. Commentary: netazepide for gastric acid suppression-another kid on the block. Aliment Pharmacol Ther 2012; 36: 294-5.